Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

University of Toronto

$105,000.00

Investigation of Gastrointestinal Adverse Events of Brand Versus Generic Osteoporosis Medications: Merits and Limitations of Different Non-Experimental Research Methods

EF 2018-19

Résumé
Osteoporosis is a condition of brittle bone which makes patients susceptible to fractures. Over 2 million Canadians are affected by osteoporosis. The bisphosphonate (BP) class of medications is widely used today for osteoporosis treatment and prevention. Medication adherence is imperative for patients taking BP, as every osteoporosis fracture is estimated to cost the Canadian healthcare system 17,000 dollars. Upper gastrointestinal (GI) complaints, such as heartburn and ulcers, are the most common reason for BP discontinuation. Generic formulations of BP, which are preferred by most insurances due to lower costs, do not have identical disintegration properties as their brand counterparts because of differences in inactive ingredients; these differences have led to inquiries about the GI safety of generic BP. Previous studies have shown that patients taking generic BP had higher rates of drug discontinuation and GI endoscopies than patients taking brand BP. However, previous studies included too few patients to obtain precise results, examined outcomes which are not reliably recorded in databases, or compared groups which had different baseline risks for GI conditions. The proposed research will describe characteristics of over 500,000 new BP users over time in Ontario; compare the rates of GI side effects between brand versus generic BP using three different non-experimental study designs; and compare results, strengths, and limitations of the designs for educational purposes. In addition to informing whether public drug formularies should include brand BP or enforce better evidence of safety of generic oral BP prior to market entry, findings will help to educate a variety of stakeholders (e.g., clinicians, policy-makers) on the implementation and interpretation of these designs.
Programme
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
404054
Name
Hayes Kaleen N
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Population and Public Health
Theme2
Social / Cultural / Environmental / Population Health
Prcname2
Doctoral Research Awards - B
Projecttitle
Investigation of Gastrointestinal Adverse Events of Brand Versus Generic Osteoporosis Medications: Merits and Limitations of Different Non-Experimental Research Methods
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Comparative Effectiveness Research; Drug Safety; Epidemiologic Methods; Gastrointestinal Health; Osteoporosis; Pharmacoepidemiology; Pharmacovigilance
Abstract
Osteoporosis is a condition of brittle bone which makes patients susceptible to fractures. Over 2 million Canadians are affected by osteoporosis. The bisphosphonate (BP) class of medications is widely used today for osteoporosis treatment and prevention. Medication adherence is imperative for patients taking BP, as every osteoporosis fracture is estimated to cost the Canadian healthcare system 17,000 dollars. Upper gastrointestinal (GI) complaints, such as heartburn and ulcers, are the most common reason for BP discontinuation. Generic formulations of BP, which are preferred by most insurances due to lower costs, do not have identical disintegration properties as their brand counterparts because of differences in inactive ingredients; these differences have led to inquiries about the GI safety of generic BP. Previous studies have shown that patients taking generic BP had higher rates of drug discontinuation and GI endoscopies than patients taking brand BP. However, previous studies included too few patients to obtain precise results, examined outcomes which are not reliably recorded in databases, or compared groups which had different baseline risks for GI conditions. The proposed research will describe characteristics of over 500,000 new BP users over time in Ontario; compare the rates of GI side effects between brand versus generic BP using three different non-experimental study designs; and compare results, strengths, and limitations of the designs for educational purposes. In addition to informing whether public drug formularies should include brand BP or enforce better evidence of safety of generic oral BP prior to market entry, findings will help to educate a variety of stakeholders (e.g., clinicians, policy-makers) on the implementation and interpretation of these designs.
Competitiondate
201810
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Hayes, Kaleen N
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~